EICHOR
● Recruiting
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Condition: Oligometastatic Renal Cell Carcinoma · Sponsor: M.D. Anderson Cancer Center
About this study
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
This description comes directly from the study's public registry record.
Talk to the study team
Chad Tang, MD · (713) 745-7179 · ctang1@mdanderson.org
Always discuss trial participation with your own doctor first.
Locations (1)
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06004336